Proactiveinvestors Australia PreveCeutical Medical Inc https://www.proactiveinvestors.com.au Proactiveinvestors Australia PreveCeutical Medical Inc RSS feed en Fri, 19 Jul 2019 07:37:10 +1000 http://blogs.law.harvard.edu/tech/rss Genera CMS action@proactiveinvestors.com (Proactiveinvestors) action@proactiveinvestors.com (Proactiveinvestors) <![CDATA[Media files - PreveCeutical prepares for the final stage of their Sol-Gel program ]]> https://www.proactiveinvestors.com.au/companies/stocktube/13122/preveceutical-prepares-for-the-final-stage-of-their-sol-gel-program-13122.html Fri, 26 Apr 2019 10:17:00 +1000 https://www.proactiveinvestors.com.au/companies/stocktube/13122/preveceutical-prepares-for-the-final-stage-of-their-sol-gel-program-13122.html <![CDATA[Media files - PreveCeutical Medical provides update on development of Sol Gel technology ]]> https://www.proactiveinvestors.com.au/companies/stocktube/12056/preveceutical-medical-provides-update-on-development-of-sol-gel-technology-12056.html Thu, 31 Jan 2019 13:57:00 +1100 https://www.proactiveinvestors.com.au/companies/stocktube/12056/preveceutical-medical-provides-update-on-development-of-sol-gel-technology-12056.html <![CDATA[Media files - PreveCeutical develops proprietary method for extracting cannabinoids for Sol-gel ]]> https://www.proactiveinvestors.com.au/companies/stocktube/10563/preveceutical-develops-proprietary-method-for-extracting-cannabinoids-for-sol-gel-10563.html Mon, 24 Sep 2018 07:00:00 +1000 https://www.proactiveinvestors.com.au/companies/stocktube/10563/preveceutical-develops-proprietary-method-for-extracting-cannabinoids-for-sol-gel-10563.html <![CDATA[News - PreveCeutical Medical stock soars, but company says not aware of reasons behind rally ]]> https://www.proactiveinvestors.com.au/companies/news/205170/preveceutical-medical-stock-soars-but-company-says-not-aware-of-reasons-behind-rally-205170.html PreveCeutical Medical Inc (CSE: PREV) (OTCQB: PRVCF) shares closed sharply higher on Tuesday, but the company said it was not aware of any reason behind the stock's surge.

"At the request of the Investment Industry Regulatory Organization of Canada (IIROC), (the company) confirms that its management is not aware of any undisclosed corporate development or material change to the company or its operations that would account for the recent increase in market activity," a statement said.

Shares of PreveCeutical in Canada closed 50% higher at C$0.06, while its stock in New York settled 53.33% stronger at US$0.46. 

BIG PICTURE: PreveCeutical Medical reaches major milestone in its Australia Sol-Gel research program

PreveCeutical is a health sciences company that develops options for preventive and curative therapies utilizing organic and nature identical products.

The company currently has five research and development programs.

They include a dual gene therapy for curative and prevention therapies for type 2 diabetes and obesity; a Sol-gel drug delivery program; Nature Identical peptides for treatment of various ailments; non-addictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury).

The company is based in Vancouver, British Columbia.

]]>
Tue, 18 Sep 2018 16:40:00 +1000 https://www.proactiveinvestors.com.au/companies/news/205170/preveceutical-medical-stock-soars-but-company-says-not-aware-of-reasons-behind-rally-205170.html
<![CDATA[News - PreveCeutical Medical shares head north as it launches medical cannabis division ]]> https://www.proactiveinvestors.com.au/companies/news/201468/preveceutical-medical-shares-head-north-as-it-launches-medical-cannabis-division-201468.html Health sciences group PreveCeutical Medical Inc (CSE:PREV) saw shares race north on Tuesday as it made a further step on its development path -  launching a medicinal cannabis division.

The business will be responsible for bringing an array of medicinal cannabis-based products to market as well as overseeing the company's nasal delivery sol-gel research program and resultant formulations.

WATCH: Preveceutical Medical making headway with cannabinoid delivery system

That program involves the testing of an array of cannabis strains to commercialise cannabinoid-based soluble gels.

According to Statista, the expanding worldwide cannabis market is estimated to reach an eye-watering US$63.5bn by 2024.

"The opening of the cannabis division at this crucial moment is very exciting and continues to move the company in an important direction," said Stephen Van Deventer, the firm's chairman, chief executive and president.

"With Canada's upcoming legalization of recreational cannabis on Oct. 17, 2018, and the reduction of the stigma surrounding cannabis products, Preveceutical sees a potential void in the medicinal cannabis sector as many companies begin to move to recreational market to accommodate demand.

"This market shift will provide Preveceutical with the opportunity to focus on the healthcare sector and supply the increasing demand for effective and tailored cannabis-based therapies."

READ: Preveceutical Medical updates investors on its soluble gel drug delivery R&D

As the company stated earlier this month, conventional methods of nasal drug delivery, such as drops and sprays, fail to deliver therapeutics far enough into the nasal cavity and are rapidly removed by the body's cleaning mechanisms.

Preveceutical's soluble gel formulations aim to resolve this by providing a fast nose-to-brain delivery of a host of therapeutic agents, including cannabinoids.

The group is developing a custom soluble gel applicator and its research partner, The University of Queensland, has received several prototype soluble gel spray devices from the group's manufacturer.

Although evaluations are ongoing, the preliminary results are promising, the company has said.

Preveceutical shares added 6.25% to C$0.0425 in Toronto.

]]>
Tue, 24 Jul 2018 10:46:00 +1000 https://www.proactiveinvestors.com.au/companies/news/201468/preveceutical-medical-shares-head-north-as-it-launches-medical-cannabis-division-201468.html
<![CDATA[Media files - Preveceutical Medical making headway with cannabinoid delivery system ]]> https://www.proactiveinvestors.com.au/companies/stocktube/9894/preveceutical-medical-making-headway-with-cannabinoid-delivery-system-9894.html Thu, 19 Jul 2018 11:36:00 +1000 https://www.proactiveinvestors.com.au/companies/stocktube/9894/preveceutical-medical-making-headway-with-cannabinoid-delivery-system-9894.html <![CDATA[News - Preveceutical Medical updates investors on its soluble gel drug delivery R&D ]]> https://www.proactiveinvestors.com.au/companies/news/200608/preveceutical-medical-updates-investors-on-its-soluble-gel-drug-delivery-rd-200608.html Health sciences firm PreveCeutical Medical Inc (CSE:PREV) said preliminary findings on its custom soluble gel applicator are encouraging as it updated on its R&D (research and development) work.

The programme involves testing an array of cannabis strains to commercialise cannabinoid-based soluble gels.

READ: PreveCeutical Medical closes oversubscribed placing and brings in C$6.54mln

Conventional methods of nasal drug delivery, such as drops and sprays, fail to deliver therapeutics far enough into the nasal cavity and are rapidly removed by the body's cleaning mechanisms.

Preveceutical's soluble gel formulations aim to resolve this by providing a fast nose-to-brain delivery of a host of therapeutic agents, including cannabinoids.

The group is developing a custom soluble gel applicator and its research partner, The University of Queensland, has received several prototype soluble gel spray devices from the group's manufacturer.

Although evaluations are ongoing, the preliminary results are promising, said the company.

Preveceutical shares are unchanged at C$0.065.

]]>
Wed, 11 Jul 2018 11:14:00 +1000 https://www.proactiveinvestors.com.au/companies/news/200608/preveceutical-medical-updates-investors-on-its-soluble-gel-drug-delivery-rd-200608.html
<![CDATA[News - PreveCeutical Medical retains Link Media for marketing services ]]> https://www.proactiveinvestors.com.au/companies/news/200506/preveceutical-medical-retains-link-media-for-marketing-services-200506.html Health sciences group PreveCeutical Medical Inc (CSE:PREV) said it had hired Link Media  to provide communications and market awareness services to the company.

This is aimed at maintaining and building the profile of the company among existing and potential investors.

Link Media is at arm’s length to the firm and will be paid US$175,000 in cash for its services.

Shares in Preveceutical are today up over 33% to stand at C$0.060.

]]>
Tue, 10 Jul 2018 11:25:00 +1000 https://www.proactiveinvestors.com.au/companies/news/200506/preveceutical-medical-retains-link-media-for-marketing-services-200506.html
<![CDATA[News - PreveCeutical Medical closes oversubscribed placing and brings in C$6.54mln ]]> https://www.proactiveinvestors.com.au/companies/news/199898/preveceutical-medical-closes-oversubscribed-placing-and-brings-in-c654mln-199898.html Health sciences company PreveCeutical Medical Inc (CSE:PREV) has closed its oversubscribed private placing, and raised C$6.54mln (gross).

In all, around 130.8mln units were issued at $0.05 per unit for gross proceeds of $6,539,987.50.

READ: Preveceutical to increase private placement to C$8mln due to investor demand

The funds were earmarked for research and development (R&D) programmes and for general working capital purposes.

"I am very pleased to announce this oversubscribed placement due to investor demand in our financing and see this as a strong endorsement of the quality of our research programmes and management team," said Stephen Van Deventer, chairman, chief executive and president of the group said.

"In keeping with our vision of becoming a global preventive health care company, PreveCeutical is continuing to meet key milestones with our portfolio of research and development programmes that will boost shareholder value."

Each unit consisted of one share and one share purchase warrant, with each warrant entitling the holder to acquire a further share for C$0.10  each for up to two years, until 29 June 2020.

Busy period

It's been a busy period for the firm. Earlier this month, the firm struck an agreement with Stadnyk & Partners to provide strategic advisory services to the company.

It will provide market awareness services to Preveceutical, and the company will issue two million stock options to Stadnyk & Partners.

In May this year, PreveCeutical said it had been awarded two additional permits by the Australian Government, Department of Health, for the importation of a second shipment of cannabis plant materials into Australia for research purposes and the shipment of dried cannabis materials.

In addition that month, it inked a non-disclosure agreement (NDA) with a globally recognized, innovative drug delivery device manufacturer.

This will allow the firm to enter discussions with the manufacturer for the supply of spray devices for use in the company's soluble gel drug delivery research program.

The aim is to apply the Sol-gel technology to cannabinoids (CBDs) to develop therapies for a range of symptoms, including pain, inflammation, seizures and neurological disorders.

Shares in Toronto are at C$0.075.

]]>
Fri, 29 Jun 2018 11:20:00 +1000 https://www.proactiveinvestors.com.au/companies/news/199898/preveceutical-medical-closes-oversubscribed-placing-and-brings-in-c654mln-199898.html
<![CDATA[News - Preveceutical to increase private placement to C$8mln due to investor demand ]]> https://www.proactiveinvestors.com.au/companies/news/199531/preveceutical-to-increase-private-placement-to-c8mln-due-to-investor-demand-199531.html Health sciences company, PreveCeutical Medical Inc. (CSE:PREV) announced today that it expects its previously-announced C$4mln non-brokered private placement 2018 will be oversubscribed due to higher-than-expected investor demand.

The company said the offering will be increased up to $8mln in gross subscription proceeds. 

Funds raised will help fund the company's research and development programs and for general working capital purposes.

READ: Preveceutical Medical announces advisory services deal with Stadnyk & Partners

The company recently announced a stock split, which was on the basis of five new shares for each one existing (5:1).

Shares of Preveceutical were down 6.25% at C$0.08 on Monday. 

]]>
Mon, 25 Jun 2018 16:23:00 +1000 https://www.proactiveinvestors.com.au/companies/news/199531/preveceutical-to-increase-private-placement-to-c8mln-due-to-investor-demand-199531.html
<![CDATA[News - Preveceutical Medical announces advisory services deal with Stadnyk & Partners ]]> https://www.proactiveinvestors.com.au/companies/news/198306/preveceutical-medical-announces-advisory-services-deal-with-stadnyk-partners-198306.html Health sciences company, PreveCeutical Medical Inc. (CSE:PREV) announced today that it has entered into an agreement with Stadnyk & Partners to provide strategic advisory services to the company.

The company will provide market awareness services to Preveceutical, and the company will issue two million stock options to Stadnyk & Partners. Of those options, one common share in the company may be acquired for C$0.08 per share for a period of 24 months. The initial agreement is for one year, subject to renewal by agreement of both parties. 

WATCH: PreveCeutical Medical Inc. receives first cannabis shipment at Australia lab

Stadnyk & Partners will provide strategic finance, merger and acquisition, and capital markets advisory services to Preveceutical to help it target its business goals during the terms of the agreement, for which three million stock options will be issued to Stadnyk & Partners. 

The founder of Stadnyk & Partners, David Stadnyk, has successfully initiated equity capital financing efforts of more than C$500mln. As an entrepreneur, he founded both private and public companies including: Pharmaxis, Eurpraxia Pharmaceuticals, Supreme Cannabis Company, Friday Night Inc and M Pharmaceutical Inc, among others.

Shares of Preveceutical were up 11.11% at C$0.10 on Tuesday. 

]]>
Tue, 05 Jun 2018 12:32:00 +1000 https://www.proactiveinvestors.com.au/companies/news/198306/preveceutical-medical-announces-advisory-services-deal-with-stadnyk-partners-198306.html
<![CDATA[News - PreveCeutical Medical's stock split to take place on May 24 ]]> https://www.proactiveinvestors.com.au/companies/news/197579/preveceutical-medical-s-stock-split-to-take-place-on-may-24-197579.html Wed, 23 May 2018 13:34:00 +1000 https://www.proactiveinvestors.com.au/companies/news/197579/preveceutical-medical-s-stock-split-to-take-place-on-may-24-197579.html <![CDATA[News - PreveCeutical Medical shareholders approve 5:1 stock split ]]> https://www.proactiveinvestors.com.au/companies/news/197218/preveceutical-medical-shareholders-approve-51-stock-split-197218.html Health sciences and preventative medicines firm PreveCeutical Medical Inc (CSE:PREV, OTCQB:PRVCF) is poised to carry out a stock split after shareholders approved the plan.

At the AGM and special meeting of shareholders on May 14, a special resolution was passed approving the proposed split on the basis of five new shares for each one existing (5:1).

READ: PreveCeutical Medical receives second Aurora cannabis shipment

"We believe the stock split demonstrates the company's continued commitment to broaden its shareholder base and we anticipate that the stock split will make PreveCeutical's securities more accessible to investors and enhance liquidity for shareholders." said president and chairman Stephen Van Deventer.

Earlier this month, the firm said it had received the second shipment of dried cannabis materials from major Aurora Cannabis, which will be used in PreveCeutical's soluble gel (Sol-gel) drug delivery research.

As revealed in March, the company, in a major milestone, had received the key permits to allow this material to be imported into Australia by the cannabis major.

It is being used for the group's research led by Preveceutical's chief research officer Dr Harendra Parekh at the University of Queensland.

Preveceutical aims to develop therapies for relief from a range of symptoms, including pain, inflammation, seizures and neurological disorders.

]]>
Thu, 17 May 2018 11:26:00 +1000 https://www.proactiveinvestors.com.au/companies/news/197218/preveceutical-medical-shareholders-approve-51-stock-split-197218.html
<![CDATA[News - PreveCeutical Medical receives second Aurora cannabis shipment ]]> https://www.proactiveinvestors.com.au/companies/news/196947/preveceutical-medical-receives-second-aurora-cannabis-shipment-196947.html PreveCeutical Medical Inc (CSE:PREV, OTCQB:PRVCF) has received the second shipment of dried cannabis materials from major Aurora Cannabis, it told investors.

The pot materials will be used in PreveCeutical's soluble gel (Sol-gel) drug delivery research.

As revealed in March, the company, in a major milestone, had received the key permits to allow this material to be imported into Australia by the  cannabis major.

It is being used for the group's research led by Preveceutical's chief research officer Dr Harendra Parekh at the University of Queensland.

Preveceutical aims to develop therapies for relief from a range of symptoms, including pain, inflammation, seizures and neurological disorders.

The advantages of Sol-gels over conventional liquid nasal sprays include reduced dosage requirements, and reduced irritation and other negative side effects.

Shares were unchanged at C$0.29.

]]>
Mon, 14 May 2018 12:57:00 +1000 https://www.proactiveinvestors.com.au/companies/news/196947/preveceutical-medical-receives-second-aurora-cannabis-shipment-196947.html
<![CDATA[News - PreveCeutical Medical signs non-disclosure agreement with leading drug delivery device manufacturer ]]> https://www.proactiveinvestors.com.au/companies/news/196485/preveceutical-medical-signs-non-disclosure-agreement-with-leading-drug-delivery-device-manufacturer-196485.html Health sciences specialist PreveCeutical Medical Inc (CSE: PREV, OTCQB: PRVCF) has signed a non-disclosure agreement (NDA) with a globally recognized, innovative drug delivery device manufacturer.

This will allow the firm to enter discussions with the manufacturer for the supply of spray devices for use in the company's soluble gel drug delivery research program. The aim is to apply the Sol-gel technology to cannabinoids (CBDs) to develop therapies for a range of symptoms, including pain, inflammation, seizures and neurological disorders

A number of prototype spray devices from the manufacturer have been provided to the company’s research partner, the University of Queensland.

READ: PreveCeutical Medical reaches major milestone in its Australia Sol-Gel research program

Led by Preveceutical's chief research officer, Dr. Harendra Parekh, research on the Sol-gel program and testing of the devices for the program is currently being conducted.

"We are pleased to have signed an NDA with this world-leading manufacturer that has set a standard for the drug delivery industry with their advanced quality products. Their recognition of the significance of safety regulations, such as tamper-proof drug delivery devices, are of the upmost importance to us,” said Preveceutical's chairman, chief executive officer and president, Stephen Van Deventer.

“Although the program is still in its preliminary stage, co-ordinating the evaluation of drug delivery devices in parallel with the Sol-gel program demonstrates Preveceutical's commitment to bringing the Sol-gel nose-to-brain delivery system to market."

WATCH: PreveCeutical Medical Inc. receives first cannabis shipment at Australia lab

The group currently runs five research and development programs, notably, its sol-gel platform for nose-to-brain delivery of medical compounds including cannabinoids and dual gene therapy for curative and prevention therapies for diabetes and obesity.

Last month, the firm received the first shipment of dried cannabis flower and oils from cannabis-mammoth Aurora Cannabis, allowing the soluble gel (Sol-gel) delivery testing to begin. Key permits were required to allow this material to be imported into Australia.

Shares on Tuesday (May 8) added 3.45% to C$0.30

]]>
Mon, 07 May 2018 11:07:00 +1000 https://www.proactiveinvestors.com.au/companies/news/196485/preveceutical-medical-signs-non-disclosure-agreement-with-leading-drug-delivery-device-manufacturer-196485.html
<![CDATA[News - PreveCeutical Medical granted two additional permits to import second shipment of cannabis plant materials into Australia ]]> https://www.proactiveinvestors.com.au/companies/news/196377/preveceutical-medical-granted-two-additional-permits-to-import-second-shipment-of-cannabis-plant-materials-into-australia-196377.html PreveCeutical Medical Inc. (CSE:PREV, OTCQB:PRVCF) said it has been awarded two additional permits by the Australian Government, Department of Health, for the importation of a second shipment of cannabis plant materials into Australia for research purposes and the shipment of dried cannabis materials.

In a statement, the company said the permits were issued to the Pharmacy Australia Centre of Excellence (PACE) at the University of Queensland (UQ).

WATCH: PreveCeutical Medical Inc. receives first cannabis shipment at Australia lab

It allows PACE to import shipments of cannabis material for research purposes.

In addition, PreveCeutical's Canadian licenced producer partner has also received the required Canadian permits to export their medical cannabis materials to PACE.

The cannabis materials are used for PreveCeutical's soluble gel (Sol-gel) drug delivery research programme, for testing an array of cannabis strains for the development and commercialisation of cannabinoid-based Sol-gels.

The programme is led by PreveCeutical's Chief Research Officer, Dr. Harendra Parekh and conducted by PreveCeutical's research partner, the University of Queensland.

Using Sol-gel technology to develop therapies

It aims to develop a technology that will increase the bioavailability of drugs by using a nose-to-brain delivery system.

By applying Sol-gel technology to cannabis, the company plans to develop therapies for relief from a range of symptoms, including pain, inflammation, seizures and neurological disorders.

The advantages of Sol-gels over conventional liquid nasal sprays include longer therapeutic effects, reduced dosage requirements, and reduced negative side effects, such as irritation.

Australia’s Department of Health has strict regulations on the procuring, possessing, using and disposing of cannabis and cannabis-derived materials that govern both the Company's production and in-vitro testing of cannabinoid-based Sol-gels.

The regulations, requires, among others, the maintenance of records of imported materials, using approved storage receptacles and restricting access and use of controlled substances to authorised persons.

A recent audit of the programme, carried out by the Department of Health, revealed that Dr. Parekh and PACE are doing exceptional work in complying with the regulations.

]]>
Thu, 03 May 2018 14:25:00 +1000 https://www.proactiveinvestors.com.au/companies/news/196377/preveceutical-medical-granted-two-additional-permits-to-import-second-shipment-of-cannabis-plant-materials-into-australia-196377.html
<![CDATA[News - Preveceutical Medical enters into C$700,000 credit facility, amends earlier financing deals ]]> https://www.proactiveinvestors.com.au/companies/news/196082/preveceutical-medical-enters-into-c700000-credit-facility-amends-earlier-financing-deals-196082.html PreveCeutical Medical Inc (CSE:PREV, OTCQB:PRVCF) told its investors that it has entered into a C$700,000 credit facility deal with its former president Kimberly Van Deventer.

In addition, the company has also amended and increased a credit facility agreement with Kimberly Van Deventer and CEO and current president Stephen Van Deventer.

READ: PreveCeutical Medical set to raise up to C$4mln for R&D programs

In a statement, the company said under the 2016 credit facility, the lenders entered into a convertible credit facility agreement with the company for a total of C$2mln.

The terms of the 2016 credit facility, states that the amount of any outstanding principal and accrued interest thereon is convertible, after 31 January 2019, into fully paid and non-assessable common shares in the capital of the company at 50 cents per share.

Preveceutical said it has drawn the full C$2mln available under the 2016 credit facility, which bears a simple interest of 5% per annum.

The lenders have signed a waiver, which provides that there will be no demand by the lenders on the funds outstanding under the 2016 credit facility until 31 January 2019.

Pursuant to an amendment to the 2016 credit facility dated 20 April 2018, and in connection with the company's 25-cent private placement, the 2016 conversion price has been cut to 30 cents per share.

2017 credit facility

The company entered into an additional convertible credit facility agreement (2017 credit facility) with its lenders for C$1mln to cover operational expenses.

Under the terms of the facility, the amount of any outstanding principal and accrued interest thereon is convertible into units in the capital of the company at a price of 50 cents per unit.

Each unit consists of one common share in the capital of the company and one transferable common share purchase warrant entitling the holder to purchase one common share at the price of $1 per share for a period of 24 months after the issuance of the units, subject to acceleration.

Any outstanding funds under the 2017 credit facility bears simple interest at a rate of 5% per annum.

The company has now reduced the 2017 conversion price to 30 cents per unit, reduced the exercise price of the warrants to 50 cents per share, and entered into a promissory note with the lenders, increasing the amount available under the 2017 credit facility agreement by C$500,000.

The lenders have also signed a waiver, which provides that there will be no demand by the lenders on the funds outstanding under the 2017 credit facility until 31 Jan 2019.

2018 credit facility

And effective 28 March 2018, the company entered into credit facility agreement with Kimberly Van Deventer for C$700,000 on a revolving basis, with any sums advanced to the company accruing interest at 5% per annum.

Under the terms of the 2018 credit facility, at any time prior to the repayment of the 2018 credit facility in full, Van Deventer has the right to convert any or all of the then outstanding advances (and the interest accrued thereon) into fully paid and non-assessable common shares in the capital of the company at the price of 50 cents per share.

The 2018 conversion price has now been reduced from 50 cents to 30 cents and the company has allowed for future adjustment of the 2018 conversion price in the event of certain share capital transactions.

Preveceutical is a health sciences company that develops innovative preventive therapies utilizing organic and nature identical products.

The company sells CELLB9, an immune system booster, containing polarized and potentiated essential minerals extracted from a novel peptide obtained from Caribbean blue scorpion venom.

]]>
Mon, 30 Apr 2018 11:59:00 +1000 https://www.proactiveinvestors.com.au/companies/news/196082/preveceutical-medical-enters-into-c700000-credit-facility-amends-earlier-financing-deals-196082.html
<![CDATA[News - PreveCeutical Medical set to raise up to C$4mln for R&D programs ]]> https://www.proactiveinvestors.com.au/companies/news/194556/preveceutical-medical-set-to-raise-up-to-c4mln-for-rd-programs-194556.html PreveCeutical Medical Inc (CSE:PREV, OTCQB:PRVCF) is set to raise up to C$4mln for its research and development (R&D) programs and for general working capital.

The health sciences group has arranged a private placement of up to 16mln units at 25 cents each for gross proceeds of up to C$4mln.

Each unit consists of one share and one warrant, with each warrant entitling the holder to buy a share for 50 cents for 24 months from closing.

The group also said that its 2018 annual general and special meeting has been set for May 11 this year in Vancouver.

Last month, the firm received the first shipment of dried cannabis flower and oils from pot giant Aurora Cannabis, which means soluble gel (Sol-gel) delivery testing can now start.

In March, the firm, in a major milestone, had received the key permits to allow this material to be imported into Australia by the cannabis major.

It will be used for the group's research led by Preveceutical's chief research officer Dr Harendra Parekh at the University of Queensland.

The group currently has five research and development programs, including dual gene therapy for curative and prevention therapies for diabetes and obesity, a sol-gel platform for nose to brain delivery of medical compounds including cannabinoids.

]]>
Mon, 09 Apr 2018 13:05:00 +1000 https://www.proactiveinvestors.com.au/companies/news/194556/preveceutical-medical-set-to-raise-up-to-c4mln-for-rd-programs-194556.html
<![CDATA[Media files - PreveCeutical Medical Inc. receives first cannabis shipment at Australia lab ]]> https://www.proactiveinvestors.com.au/companies/stocktube/9006/preveceutical-medical-inc-receives-first-cannabis-shipment-at-australia-lab-9006.html Fri, 06 Apr 2018 09:23:00 +1000 https://www.proactiveinvestors.com.au/companies/stocktube/9006/preveceutical-medical-inc-receives-first-cannabis-shipment-at-australia-lab-9006.html <![CDATA[News - PreveCeutical Medical gets first Aurora cannabis shipment ]]> https://www.proactiveinvestors.com.au/companies/news/194062/preveceutical-medical-gets-first-aurora-cannabis-shipment-194062.html PreveCeutical Medical Inc (CSE:PREV, OTCQB:PRVCF) said it had received the first shipment of dried cannabis flower and oils from Aurora Cannabis, which means soluble gel (Sol-gel) delivery testing can now start.

As revealed earlier this month, the firm, in a major milestone, had received the key permits to allow this material to be imported into Australia by the  cannabis major.

It will be used for the group's research led by Preveceutical's chief research officer Dr Harendra Parekh at the University of Queensland.

"Testing of the imported cannabis strains in the application of soluble gel (Sol-gel) drug-delivery technology to cannabinoids is now expected to commence," said the firm in a brief statement.

"The purpose of the testing will be to develop therapies for relief from a range of symptoms, including pain, inflammation, seizures and neurological disorders."

The advantages of Sol-gels over conventional liquid nasal sprays include reduced dosage requirements, and reduced irritation and other negative side effects.

Shares in the group shed 1.35% to stand at C$0.36 each.

]]>
Thu, 29 Mar 2018 11:38:00 +1100 https://www.proactiveinvestors.com.au/companies/news/194062/preveceutical-medical-gets-first-aurora-cannabis-shipment-194062.html
<![CDATA[News - PreveCeutical Medical reaches major milestone in its Australia Sol-Gel research program ]]> https://www.proactiveinvestors.com.au/companies/news/193411/preveceutical-medical-reaches-major-milestone-in-its-australia-sol-gel-research-program-193411.html Health care and preventative medicine firm PreveCeutical Medical Inc (CSE:PREV, OTCQB:PRVCF) has seen a big leap forward with one of its programs  in recent days - the Sol-Gel nasal delivery work.

The group has received key permits to allow cannabis - flowers and oils -  to be imported into Australia from major pot group Aurora Cannabis Inc  (TSE:ACB) and used for the group's research led by Preveceutical's chief research officer Dr Harendra Parekh.

The aim is to apply the Sol-gel technology to cannabinoids (CBDs) to develop therapies for a range of symptoms, including pain, inflammation, seizures and neurological disorders

Recently, Parekh and chief executive  Stephen Van Deventer told Proactive they had received interest from leading hospitals about trialling the formulations, when ready.

WATCH - PreveCeutical seeing significant hospital interest for breakthrough Cannabidiol treatment

Three permits were granted by the Australian government, Department of Health. They were granted to the Pharmacy Australia Centre of Excellence (PACE) at the University of Queensland (UQ), where the research will be carried out.

The firm has also now announced that it has opened a subsidiary in Australia to allow PreveCeutical to better access expertise and partnerships for its drug development programs,

Parekh said the hope is that in around 18-14 months, clinical trials will be able to start - focusing on using the treatment for palliative care.

"We see an important market for cannabis-based products that are more narrowly targeted at specific therapeutic areas but that are higher value add and being involved with initiatives such as PreveCeutical's is part of our strategy to gain access to these types of products," Aurora, which will supply the cannabis, said.

It comes as the legal cannabis market continues to grow, notably in Canada. But the Preveceutical team sees this as a global opportunity.

"The cannabis market is growing fast as more states and countries legalize its use for both medical and recreational purposes," said a recent article on NetworkNewsWire.

"This is allowing companies to invest heavily in cannabis research to develop drugs and other products for this growing market. Research and design is becoming increasingly important."

The news service has also said: "Driven by a growing need for pain mitigation and increased awareness of potential health benefits, the global market for CBD is growing at a 39% compound annual growth rate."

Plenty of other irons in fire..

Apart from the Sol-gel platform for nose-to-brain delivery,  PreveCeutical also has other R&D (research and development) programs.

These are: a dual gene therapy for curative and prevention therapies for diabetes and obesity. It is also working on developing non-addictive analgesic peptides as a replacement to highly addictive analgesics such as morphine and fentanyl, and has a therapeutic product for treating athletes who suffer from concussions.

PreveCeutical Medical shifting the dial in pain management solutions, suggests article

Last month, PreveCeutical entered into a research and option agreement with the University of Queensland (UQ) and UniQuest, the university’s main commercialisation company - the fourth agreement the pair has signed over the past 12 months, to develop the non-addictive pain killers.

The global market for pain management drugs exceeded $62 billion in 2016 and is estimated to surpass $88 billion by 2025, according to one report.

PreveCeutical will own all intellectual property (IP) and UniQuest, the IP and research commercialization company of the University of Queensland, will receive payments for development milestones and sales-based royalties.

Scorpion venom..

Interestingly, the company is also working on a program related to Caribbean Blue Scorpion venom, which has been shown to impact aggressive cancers, such as breast and brain.

In January this year, the firm said its peptide research and development program was progressing on schedule through the first of three phases.

The team is working to sequence the extracted peptides and proteins to determine their amino acid fingerprint.

So there looks to be plenty of newsflow coming for investors in 2018 and beyond from this emerging company.

]]>
Mon, 19 Mar 2018 05:05:00 +1100 https://www.proactiveinvestors.com.au/companies/news/193411/preveceutical-medical-reaches-major-milestone-in-its-australia-sol-gel-research-program-193411.html
<![CDATA[News - PreveCeutical Medical opens up a subsidiary in Australia ]]> https://www.proactiveinvestors.com.au/companies/news/193328/preveceutical-medical-opens-up-a-subsidiary-in-australia-193328.html Health sciences group PreveCeutical Medical Inc (CNSX:PREV) has opened a subsidiary in Australia.

The team down under will be led by PreveCeutical's director of international operations, Dr Maher Khaled, who will work closely with the company’s chief research officer, Dr Harry Parekh, to advance the development of the company’s therapeutic technologies.

PreveCeutical said its decision to open up an Aussie division was influenced by Australia’s strong foundation of academic and clinical research, as well as the Australian government’s commitment to supporting innovation through a range of programs and incentives. Such incentives include the research and development (R&D) tax incentive, whereby the Australian government encourages companies to engage in R&D benefiting Australia by providing a tax offset for eligible R&D activities. The current annual refundable tax offset under the program is 43.5%.

“Establishing a business presence in Australia will allow PreveCeutical to better access expertise and partnerships for its drug development programs,” predicted Dr Khaled.

“Many specialized Australian hospitals have strong clinical trial capabilities as well as the diverse patient populations needed for the range of products PreveCeutical is currently developing. Combined with Australia’s favourable regulatory regime for clinical trials, these benefits make Australia an attractive location for product development in preparation for commercialisation through the company’s established North American networks,” he added.    

]]>
Fri, 16 Mar 2018 15:19:00 +1100 https://www.proactiveinvestors.com.au/companies/news/193328/preveceutical-medical-opens-up-a-subsidiary-in-australia-193328.html
<![CDATA[News - PreveCeutical Medical set to benefit from growing legal cannabis market ]]> https://www.proactiveinvestors.com.au/companies/news/193261/preveceutical-medical-set-to-benefit-from-growing-legal-cannabis-market-193261.html As the legal cannabis market continues to grow, new deals are creating opportunities for companies like health sciences group PreveCeutical Medical Inc (CSE:PREV, OTCQB:PRVCF), says an article on NetworkNewsWire.

This week, the junior firm reached a major milestone for its Sol-Gel research programme - receiving permits to allow cannabis to be imported into Australia.

Notably, the cannabis will be provided by major firm Aurora Cannabis Inc (TSE:ACB).

READ - PreveCeutical Medical boosted as major pot group Aurora set to export cannabis to Australia for its research programme

A licensed producer under the Canadian government’s medical cannabis regulations, Aurora has over 175,000 sq ft of production facilities, allowing it to provide large volumes of high-grade medical cannabis for customers such as PreveCeutical, the article said.

"The cannabis market is growing fast as more states and countries legalise its use for both medical and recreational purposes," it added.

"This is allowing companies to invest heavily in cannabis research to develop drugs and other products for this growing market. Research and design is becoming increasingly important."

The research in Australia is being conducted by PreveCeutical's research partner UniQuest Pty Inc and led by PreveCeutical's chief research officer Dr Harendra Parekh.

PreveCeutical aims to apply Sol-gel technology to cannabinoids (CBDs) to develop therapies for a range of symptoms, including pain, inflammation, seizures and neurological disorders.

WATCH - PreveCeutical seeing significant hospital interest for breakthrough Cannabidiol treatment

The programme will be built around PreveCeutical’s innovative sol-gel nasal drug delivery system.

The aim is to develop sol-gels that deliver CBDs - active, non-psychotropic ingredients from cannabis -  more effectively into the patient’s system.

"The research team’s hope is that, through a more direct nose-to-brain delivery system, they can provide faster, more effective relief using a time-release, nano-bubble technology."

Preveceutical Medical shares are up 3.57% to C$0.44 each.

]]>
Thu, 15 Mar 2018 12:06:00 +1100 https://www.proactiveinvestors.com.au/companies/news/193261/preveceutical-medical-set-to-benefit-from-growing-legal-cannabis-market-193261.html
<![CDATA[News - PreveCeutical Medical boosted as major pot group Aurora set to export cannabis to Australia for its research programme ]]> https://www.proactiveinvestors.com.au/companies/news/193104/preveceutical-medical-boosted-as-major-pot-group-aurora-set-to-export-cannabis-to-australia-for-its-research-programme-193104.html Health sciences group PreveCeutical Medical Inc (CSE:PREV, OTCQB:PRVCF) has reached a major milestone for its Sol-Gel research programme - receiving permits to allow cannabis to be imported into Australia.

The  flower and oils will be shipped from Canada by major pot group Aurora Cannabis Inc  (TSE:ACB) and used for the group's drug delivery research programme.

"We are extremely excited to receive the permits, allowing us to further our Sol-gel research programme with the high quality cannabis products provided by Aurora," said Stephen Van Deventer, chief executive and chairman of the group.

"The goal of the programme is to cultivate a range of therapies that will benefit people with ailments such as epilepsy, pain and inflammation, safely and economically."

Three permits were granted by the Australian government, Department of Health. They were granted to the Pharmacy Australia Centre of Excellence (PACE) at the University of Queensland (UQ) .

The research is being conducted by PreveCeutical's research partner UniQuest Pty Inc and led by PreveCeutical's chief research officer Dr Harendra Parekh.

PreveCeutical aims to apply Sol-gel technology to cannabinoids to develop therapies for a range of symptoms, including pain, inflammation, seizures and neurological disorders.

The advantages of Sol-gels over conventional liquid nasal sprays include longer therapeutic effects, reduced dosages, and less irritation, the company noted.

For the shipment, Aurora has received certain rights, including the option to either license, on a non-exclusive basis, the technology for Canada and Australia, or to opt for a royalty arrangement on product sales, as well as to buy PreveCeutical shares.

"We see an important market for cannabis-based products that are more narrowly targeted at specific therapeutic areas but that are higher value add and being involved with initiatives such as PreveCeutical's is part of our strategy to gain access to these types of products," said Terry Booth, Aurora's chief executive.

Aurora operates a 55,200 sq ft state-of-the-art production facility in Mountain View County, Alberta, known as 'Aurora Mountain', and a second 40,000 sq ft high-technology production facility known as 'Aurora Vie' in Pointe-Claire, Quebec on Montreal's West Island.

In January this year,  Aurora's 800,000 square foot flagship cultivation facility, Aurora Sky, located at the Edmonton International Airport, was licensed.

Once at full capacity, this is expected to produce over 100,000 kg a year of cannabis.

]]>
Tue, 13 Mar 2018 12:48:00 +1100 https://www.proactiveinvestors.com.au/companies/news/193104/preveceutical-medical-boosted-as-major-pot-group-aurora-set-to-export-cannabis-to-australia-for-its-research-programme-193104.html
<![CDATA[Media files - PreveCeutical seeing significant hospital interest for breakthrough Cannabidiol treatment ]]> https://www.proactiveinvestors.com.au/companies/stocktube/8813/preveceutical-seeing-significant-hospital-interest-for-breakthrough-cannabidiol-treatment-8813.html Tue, 27 Feb 2018 14:20:00 +1100 https://www.proactiveinvestors.com.au/companies/stocktube/8813/preveceutical-seeing-significant-hospital-interest-for-breakthrough-cannabidiol-treatment-8813.html <![CDATA[News - PreveCeutical Medical names Dr Maher Khaled as director of international operations ]]> https://www.proactiveinvestors.com.au/companies/news/192205/preveceutical-medical-names-dr-maher-khaled-as-director-of-international-operations-192205.html Health sciences specialist PreveCeutical Medical Inc (CSE: PREV, OTCQB: PRVCF) says it has hired Dr Maher Khaled as its director of international operations.

Khaled will work closely with Dr Harry Parekh, PreveCeutical’s chief research officer, in overseeing the development of therapeutic technologies, as well as managing operations in Australia. 

READ - PreveCeutical Medical moving the needle on cannabinoid drug delivery, says NetworkNewsWire

He will also be reviewing acquisition and licensing opportunities and leading PreveCeutical’s commercialisation efforts for its growing portfolio of intellectual property (IP).

“We are delighted to have Dr. Khaled as part of our team,” said Stephen Van Deventer, the chairman and chief executive.

“Dr Khaled’s degrees in law and science, as well as his experience in commercialising therapeutic and diagnostic technologies will be of tremendous benefit to PreveCeutical and its shareholders.”

WATCH: PreveCeutical seeing significant hospital interest for breakthrough Cannabidiol treatment

He holds a PhD in Biotechnology, a BSc in Biomedical Science and a Bachelor of Laws (LLB)  and has commercialised therapeutic and diagnostic technologies for over a decade, most recently at UniQuest, where he managed intellectual property arising from medical research at the University of Queensland, Australia. 

He was also at the University of Cambridge in the UK for over six years, where he was an investment manager with Cambridge Enterprise Seed Funds.

PreveCeutical currently has five R&D (research and development) programs, including dual gene therapy for curative and prevention therapies for diabetes and obesity; a Sol-gel platform for nose-to-brain delivery of medical compounds including cannabinoids; Nature Identical peptides for treatment of various ailments; non-addictive analgesic peptides as a replacement to highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury).

]]>
Mon, 26 Feb 2018 10:45:00 +1100 https://www.proactiveinvestors.com.au/companies/news/192205/preveceutical-medical-names-dr-maher-khaled-as-director-of-international-operations-192205.html
<![CDATA[News - PreveCeutical Medical moving the needle on cannabinoid drug delivery, says NetworkNewsWire ]]> https://www.proactiveinvestors.com.au/companies/news/192077/preveceutical-medical-moving-the-needle-on-cannabinoid-drug-delivery-says-networknewswire-192077.html PreveCeutical Medical Inc (CSE: PREV, OTCQB: PRVCF) is establishing a new paradigm in cannabinoid drug delivery, says an article in NetworkNewsWire.

Cannabidiol (CBD) is a non-psychoactive compound found in the cannabis plant and is now widely used to treat chronic pain, multiple sclerosis and other conditions.

Some evidence even suggests it can prevent symptoms of Alzheimer’s and appears to promote the death of cancer cells.

Read the article here..

Driven by a growing need for pain mitigation and increased awareness of potential health benefits, the global market for CBD is growing at a 39% compound annual growth rate, the report says.

Smallcap health sciences group PreveCeutical Medical Inc (CSE: PREV, OTCQB: PRVCF) is "engineering a unique Sol-gel nose-to-brain delivery platform to provide direct, controlled pharmacological drug release".

Many large Canadian firms may find PreveCeutical’s platform superior to current dosing techniques, it added.

These include Canopy Growth Corp (TSX: WEED), Aphria Inc. (TSX: APH) and Isodiol International Inc (CSE: ISOL).

PreveCeutical currently has five R&D (research and development) programs, including dual gene therapy for curative and prevention therapies for diabetes and obesity; a Sol-gel platform for nose-to-brain delivery of medical compounds including cannabinoids; Nature Identical peptides for treatment of various ailments; non-addictive analgesic peptides as a replacement to highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury).

]]>
Thu, 22 Feb 2018 10:56:00 +1100 https://www.proactiveinvestors.com.au/companies/news/192077/preveceutical-medical-moving-the-needle-on-cannabinoid-drug-delivery-says-networknewswire-192077.html
<![CDATA[News - PreveCeutical Medical shifting the dial in pain management solutions, suggests article ]]> https://www.proactiveinvestors.com.au/companies/news/191171/preveceutical-medical-shifting-the-dial-in-pain-management-solutions-suggests-article-191171.html PreveCeutical Medical Inc (CSE: PREV, OTCQB: PRVCF), the health sciences group,  is establishing a new paradigm in pain management solutions, says a report in NetworkNewsWire.

The company is using a novel approach in developing non-addictive analgesics by engineering peptides into efficient pain blockers, eliminating highly addictive opioids, the article says.

It comes after last week's announcement of the company's research and option agreement with the University of Queensland (UQ) and UniQuest, the university’s main commercialisation company to develop non addictive painkillers, with a targeted start date for the research of March 1.

Fourth agreement

It was the fourth agreement the pair has signed over the past 12 months.

"Whether acute or chronic, caused by disease, trauma or neural damage, current pain therapeutics primarily rely on a variety of opioid-based pharmacological therapies that have ignited a severe public health crisis," the NetworkNewsWire article states.

There is a "global quest for effective opioid free medications", it added.

"...the global market for pain management drugs exceeded $62 billion in 2016 and is estimated to surpass $88 billion by 2025," it also wrote.

Highly addictive.

"Opioid-based drugs are the leading treatments for severe and chronic pain, but they can be highly addictive. Their abuse results in thousands of overdose deaths in the United States annually."

The article says "in what may be a breakthrough approach to address the critical demand for non-additive pain medications", PreveCeutical was to engineer peptides with greatly increased stability and potency and develop non-addictive analgesics for moderate-to-severe pain.

“This is a very exciting and important program as we focus on engineering a novel class of drugs derived from our very own endogenous pain pathways, for example when pain and inflammatory insults occur," said Dr Harry Parekh, PreveCeutical’s chief research officer.

"Our preliminary work has highlighted that by using our proprietary linker technology we can enhance stability while maintaining, and in some cases enhancing the potency of lead bioactives."

The four-phase research program will be led by Dr Parekh and carried out in collaboration with pain and inflammation pharmacology experts at the University of Queensland.

PreveCeutical will own all intellectual property (IP) and UniQuest, the IP and research commercialization company of the University of Queensland, will receive payments for development milestones and sales-based royalties in accordance with the terms of the research agreement.

PreveCeutical currently has five R&D programs, including: dual gene therapy for curative and prevention therapies for diabetes and obesity; a Sol-gel platform for nose-to-brain delivery of medical compounds including cannabinoids; Nature Identical peptides for treatment of various ailments; non-addictive analgesic peptides as a replacement to highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury).

]]>
Mon, 05 Feb 2018 12:32:00 +1100 https://www.proactiveinvestors.com.au/companies/news/191171/preveceutical-medical-shifting-the-dial-in-pain-management-solutions-suggests-article-191171.html
<![CDATA[News - PreveCeutical Medical's research partner UniQuest hails pair’s painkiller research ]]> https://www.proactiveinvestors.com.au/companies/news/191031/preveceutical-medical-s-research-partner-uniquest-hails-pairs-painkiller-research-191031.html PreveCeutical Medical Inc's  (CSE: PREV, OTCQB: PRVCF) research partner in Australia, UniQuest, has hailed the pair's new agreement to develop non-addictive painkillers.

As reported on Tuesday this week,  PreveCeutical entered into a research and option agreement with the University of Queensland (UQ) and UniQuest, the university’s main commercialisation company.

It is the fourth agreement the pair has signed over the past 12 months.

UniQuest chief executive Dr Dean Moss said the aim was to prevent pain through a different mechanism to the available opioid receptor drugs such as morphine, codeine and fentanyl.

“The hope is that this would avoid the associated effects of euphoria, tolerance and dependence that lead to overdose,” he said.

“An alternative analgesic could help address global concerns over the addictive nature – and subsequent deaths by overdose – of existing opioid drugs.”

The programme has a targeted start date of March 1 this year, and will be led by UQ researcher and PreveCeutical’s chief research officer Dr Harendra Parekh, in collaboration with the UQ School of Pharmacy’s pain and inflammation pharmacology expert, associate professor Peter Cabot.

It is worth noting that the Federal Government in Australia will ban over-the-counter sales of painkillers containing codeine from today (February1), bringing Australia into line with the US, Japan and much of Europe.

]]>
Thu, 01 Feb 2018 16:00:00 +1100 https://www.proactiveinvestors.com.au/companies/news/191031/preveceutical-medical-s-research-partner-uniquest-hails-pairs-painkiller-research-191031.html
<![CDATA[News - PreveCeutical Medical inks research agreement with University of Queensland to develop non-addictive painkillers ]]> https://www.proactiveinvestors.com.au/companies/news/190850/preveceutical-medical-inks-research-agreement-with-university-of-queensland-to-develop-non-addictive-painkillers-190850.html PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) has entered into a research and option agreement with the University of Queensland (UQ) and UniQuest Pty Limited, the university’s main commercialisation company to develop non-addictive painkillers.

Under the agreement, PreveCeutical said the parties intend to conduct a research programme which expands the use of their disulfide linker technology and seeks to develop non-addictive analgesics for the treatment of pain, which may offer an alternative to addictive opioids. 

The health sciences company – which develops innovative preventive therapies utilising organic and nature identical products - noted that the US opioid epidemic has led to significant numbers of opioid-related deaths and addictions, taxing public health care systems and affecting social and economic welfare.

The group said the multiphase research program will involve peptide library synthesis pharmacological evaluation, and acute pharmacokinetic assessment and efficacy determinations in appropriate models of pain and inflammation.

The programme has a targeted start date of  1 March 2018, and will be led by UQ researcher and PreveCeutical’s chief research officer, Dr. Harendra Parekh, in collaboration with the UQ School of Pharmacy’s pain and inflammation pharmacology expert, associate professor Peter Cabot.

PreveCeutical said, under the agreement, it will own all intellectual property developed under the research program and will be granted an option to negotiate an exclusive, worldwide licence to UniQuest’s background intellectual property. 

As consideration for the licence, the company will pay UniQuest sales-based royalties and certain amounts upon the achievement of predetermined development milestones. 

]]>
Tue, 30 Jan 2018 10:42:00 +1100 https://www.proactiveinvestors.com.au/companies/news/190850/preveceutical-medical-inks-research-agreement-with-university-of-queensland-to-develop-non-addictive-painkillers-190850.html
<![CDATA[News - PreveCeutical Medical recognized as innovator by NetworkNewsWire ]]> https://www.proactiveinvestors.com.au/companies/news/190705/preveceutical-medical-recognized-as-innovator-by-networknewswire-190705.html PreveCeutical Medical Inc. (CSE:PREV, OTCQB:PRVCF) has been recognized by NetworkNewsWire for its innovative use of organic and nature identical products to develop its preventive therapies.

The Vancouver-based company develops innovative preventive therapies using organic and what it calls “nature identical” products.

It was cited in the editorial specifically for its cannabidiol (CBD)-based nose-to-brain delivery system for the relief of several medical conditions.

The editorial also touted the company’s diverse portfolio and multiple market opportunities that focus on treating diabetes, obesity, pain management, neurological disorders and cancer.

“Our bullish view on PreveCeutical Medical is influenced by the Company’s plans to bring novel therapeutic compounds to the market at a time when the preventative health care market is entering a period of rapid growth,” the article said.

READ: PreveCeutical Medical's blue scorpion venom program on track

Among its unique products is CELLB9, an oral solution derived from peptides found in blue scorpion venom.

PreveCeutical engages in five research and development programs: dual gene therapy for diabetes and obesity; a Sol-gel platform for nose-to-brain delivery of medical compounds including cannabinoids; Nature Identical™ peptides for treatment of various ailments; non-addictive analgesic peptides as a replacement to highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes suffering from concussions.

Shares were trading sharply higher to US$0.58 in afternoon trading.

  ]]>
Fri, 26 Jan 2018 14:25:00 +1100 https://www.proactiveinvestors.com.au/companies/news/190705/preveceutical-medical-recognized-as-innovator-by-networknewswire-190705.html
<![CDATA[News - PreveCeutical Medical's blue scorpion venom program on track ]]> https://www.proactiveinvestors.com.au/companies/news/190573/preveceutical-medical-s-blue-scorpion-venom-program-on-track-190573.html Health sciences group PreveCeutical Medical Inc (CSE:PREV, OTCQB:PRVCF) updated on its peptide research and development program based on the venom of the Caribbean blue scorpion.

The firm is developing innovative preventive therapies using organic and nature identical products.

Venom from the scorpion has been shown to impact aggressive cancers, such as breast and brain.

The program is progressing on schedule through the first of its three distinct phases. Preveceutical said today.

As reported last summer, the company successfully separated several target scorpion-venom-derived peptides and proteins.

Now, the research team is working to sequence the extracted peptides and proteins to determine their amino acid fingerprint.

In addition the group is currently using high-performance liquid chromatography (HPLC) to separate the target peptides and proteins before they are sequenced.

PreveCeutical's team is also trialling the application of liquid chromatography tandem-mass spectrometry (LC-MS/MS) whereby the extracted peptides and proteins are fragmented using an ion source, and each fragment is identified by its mass-to-charge ratio.

Ultimately, this process is expected to enable the company to generate Nature IdenticalTM peptides.

]]>
Wed, 24 Jan 2018 11:42:00 +1100 https://www.proactiveinvestors.com.au/companies/news/190573/preveceutical-medical-s-blue-scorpion-venom-program-on-track-190573.html
<![CDATA[News - PreveCeutical Medical to accept bitcoin for its dietary supplement ]]> https://www.proactiveinvestors.com.au/companies/news/190039/preveceutical-medical-to-accept-bitcoin-for-its-dietary-supplement-190039.html PreveCeutical Medical Inc (CNSX:PREV, OTCMKTS:PRVCF) has become another firm to embrace blockchain technology.

The preventative healthcare firm said today it will now accept bitcoin as a payment method for its Cellb9 product via BitPay Inc.

READ: PreveCeutical Medical Inc surges after cash infusion

Cellb9 is a dietary supplement treatment containing peptides from the Caribbean Blue scorpion and several customers inquired whether they could use their coins to purchase it.

"Bitcoin is a cryptocurrency which was introduced in 2009. Since its introduction, bitcoin has gained rapid popularity and entered the mainstream as the Canadian and international markets have demonstrated a move toward greater blockchain adoption," the company said in a regulatory statement.

"I'm pleased to bring bitcoin as a new payment option to our customers. Accepting bitcoin will allow us to receive both local and international payments with ease and without third party interruptions," added Stephen Van Deventer, chairman and chief executive.

The firm is advancing innovative preventive therapies using organic and nature identical products.

It currently has five research and development (R&D) programs, including dual gene therapy for diabetes and obesity, a Sol-gel platform for nose to brain delivery of medical compounds including cannabinoids.

READ: PreveCeutical Medical's Sol-Gel programme boosted by Australian state approval

It also has nature identical peptides for treatment of various ailments; non-addictive analgesic peptides as a replacement to highly addictive analgesics such as morphine, fentanyl and oxycodone.

It also has a product for treating athletes who suffer from concussions (mild traumatic brain injury).

]]>
Mon, 15 Jan 2018 09:48:00 +1100 https://www.proactiveinvestors.com.au/companies/news/190039/preveceutical-medical-to-accept-bitcoin-for-its-dietary-supplement-190039.html
<![CDATA[News - PreveCeutical Medical Inc surges after cash infusion ]]> https://www.proactiveinvestors.com.au/companies/news/187665/preveceutical-medical-inc-surges-after-cash-infusion-187665.html PreveCeutical Medical Inc's (CNSX:PREV, OTCMKTS:PRVCF) stock shot up on Wednesday morning after it announced a fully subscribed non-brokered private placement.

The company plans to raise gross proceeds of C$3.28mln through the issue of up to 4,377,776 units at a price of 75 cents per unit.

Each unit will consist of one PreveCeutical share and one warrant, with the latter convertible into a PreveCeutical common shares at 90 cents.

PreveCeutical's shares currently trade at C$0.63, up six cents on the day.

Funds from the share issue are earmarked for research and development (R&D) programs and for general working capital purposes.

PreveCeutical currently has five R&D programs, including: dual gene therapy for curative and prevention therapies for diabetes and obesity; a Sol-gel platform for nose-to-brain delivery of medical compounds including cannabinoids; Nature Identical peptides for treatment of various ailments; non-addictive analgesic peptides as a replacement to highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury).

]]>
Wed, 22 Nov 2017 10:11:00 +1100 https://www.proactiveinvestors.com.au/companies/news/187665/preveceutical-medical-inc-surges-after-cash-infusion-187665.html
<![CDATA[News - PreveCeutical Medical's Sol-Gel programme boosted by Australian state approval ]]> https://www.proactiveinvestors.com.au/companies/news/186600/preveceutical-medical-s-sol-gel-programme-boosted-by-australian-state-approval-186600.html Health sciences group PreveCeutical Medical Inc (CSE:PREV, OTCQB:PRVCF) received a major boost to its Sol-Gel research programme - gaining Australian state approval to acquire and use cannabis oil and dried cannabis plant extracts.

As reported last month, the smallcap struck a research and development supply deal with a licensed producer (LP) of medical cannabis.

READ THE BIG PIC HERE - PreveCeutical Medical bidding to be big player in preventive healthcare

This group will supply PreveCeutical with cannabis products it will use in its bid to commercialise sol-gels for the nasal delivery of medical compounds, including cannabinoids.

Today's permit means the group can now apply for the all important importation permit.

"The approval is a significant milestone which enables Preveceutical's chief research officer, Dr. Harendra Parekh, to apply for an importation permit with the Office of Drug Control in Canberra (the Australian federal-level authority)," said Preveceutical in a brief regulatory statement.

READ - PreveCeutical Medical appoints chief scientific officer to board of directors

The sol-gel research and development programme is currently being conducted in Brisbane, Australia, led by Dr Parekh.

"We are extremely pleased to receive this approval as it brings us one step closer to bringing the sol-gel nose-to-brain delivery system to market," said the firm's chairman and chief executive Stephen Van Deventer.

]]>
Wed, 01 Nov 2017 10:46:00 +1100 https://www.proactiveinvestors.com.au/companies/news/186600/preveceutical-medical-s-sol-gel-programme-boosted-by-australian-state-approval-186600.html
<![CDATA[News - PreveCeutical Medical appoints chief scientific officer to board of directors ]]> https://www.proactiveinvestors.com.au/companies/news/186292/preveceutical-medical-appoints-chief-scientific-officer-to-board-of-directors-186292.html PreveCeutical Medical Inc (CSE:PREV) has appointed its chief scientific officer Dr Makarand Jawadekar to the board of directors.

His arrival follows the departure of director and vice president of corporate development Brian Harris, who resigned from his position on Tuesday (October 24).

Jawadekar, who counts pharma giant Pfizer Inc (NYSE:PFE) among his former employers, will continue in his role as SCO as well, PreveCeutical said.

“We are delighted to welcome Dr Jawadekar to PreveCeutical’s board of directors,” said chairman and chief executive Stephen Van Deventer.

“His exceptional knowledge in drug delivery technologies and experience in the pharmaceutical industry will be of tremendous benefit to the company.”

Shares were untraded at C$0.65 on Thursday morning.

]]>
Thu, 26 Oct 2017 10:34:00 +1100 https://www.proactiveinvestors.com.au/companies/news/186292/preveceutical-medical-appoints-chief-scientific-officer-to-board-of-directors-186292.html
<![CDATA[News - PreveCeutical Medical bidding to be big player in preventive healthcare ]]> https://www.proactiveinvestors.com.au/companies/news/185363/preveceutical-medical-bidding-to-be-big-player-in-preventive-healthcare-185363.html In a world where preventive medicine is gaining so much traction, PreveCeutical Medical Inc (CSE:PREV, OTCQB:PRVCF) is bidding to grab a large share of this massive pie.

"Medicine has been, basically, you've cut yourself, you put a Band-Aid on. We are doing the opposite. We're putting a skin coating on you so you can cut yourself," explains Stephen Van Deventer, chief executive at the new Canada-listed start up, on the firm's basic focus.

He describes his as a 'preventive healthcare' company, which sets itself apart from rest of the field due, mainly, to its world class management and cutting edge technologies.

Promising upside..

And the upside for investors looks promising too.

Van Deventer aims to grow the firm's valuation from its current $40mln market cap to $1bn plus in the next few years simply via its intellectual property (IP).

The firm has several programs on the go but among the most eye-catching perhaps is its work on the venom from the Caribbean Blue Scorpion, which has been shown to impact aggressive cancers, such as breast and brain.

Van Deventer said he came across a doctor, who for over 15 years, treated over 10,000 people combined with the venom for cancer and arthritis in the Dominican Republic and Cuba with great success.

PreveCeutical's Chief Science Officer Dr Mak Jawadekar is now directing a pre-clinical research and development program to synthesize the venom, to register the synthetic product as an IND (Investigational New Drug)

The company is already selling CELLB9 on the internet -  a dietatary supplement treatment containing peptides from the scorpion, the aim is to increase revenues considerably by a marketing campaign.

Targetting Far East and Middle East..

Markets aimed at initially for the venom products will be in the Far East and Middle East, while a version for pets is being put together for North America and the West, where Van Deventer says people are not so amenable to the venom as a treatment idea.

Elsewhere, and here's the big one.... the group's dual gene therapy has 'massive' potential, says Van Deventer, as it represents a potential cure for both diabetes and obesity.

These are arguably the two biggest health problems plaguing our planet today and have a US$1.3trn a year financial impact to the planet, suggests the company boss.

The firm has found out what gene pre-disposes a person to have the conditions and is now working on a gene -silencing technology.

"We are less than four years away from proving that and applying for an IND (investigational new drug)," explains Van Deventer.

And these are not the only irons in the fire. The group also signed a letter of intent in August on a painkiller, it says, is stronger than Fentanyl and morphine, in a deal which should close this month (October).

It is non-addictive, and should have a fairly quick route to market, reckons Van Deventer.

Delivering patented system..

Last but not least, the firm's Sol-Gel program is delivering a patented system, which can deliver any kind of drug, but the focus now is cannabinoids, via the nose and can be used in adults and children too.

The benefit is that as the gel stays in the naval cavity and is released, bypasses the liver, kidney’s and digestive track, and so smaller amounts of the drug can be used, costing less with greater efficiency.

The program received a huge boost last month, when it struck a research and development supply deal with a licensed Canadian producer (LP) of medical cannabis. The LP will supply PreveCeutical with cannabis oil and dried cannabis plant extract.

An import permit is expected this year so Preveceutical can begin importing cannabis from Canada to Australia so it can start developing the treatments.

To sum up for investors, Van Deventer says investors should look at the strength of the management team he has assembled to assess the group's potential.

"None of our people would sign up if they thought it would be a failure. Let’s bet on the jockey’s not the horse, however in this case we have both the Jockey’s and horses." he suggests.

That list of management includes Dr Mak Jawadekar, who  was with drugs giant Pfizer for 28 years. Dr Harry Parekh, chief research officer, is a senior lecturer at the University of Queensland, Australia, and Brian Harris, VP of corporate development,  was the founder of what is now Ticketmaster.

So PreveCeutical's portfolio is certainly quite eye-catching and its plans to grow in a rapidly expanding market are ambitious. Preveceutical could certainly be  one to watch in coming months.

]]>
Tue, 10 Oct 2017 11:17:00 +1100 https://www.proactiveinvestors.com.au/companies/news/185363/preveceutical-medical-bidding-to-be-big-player-in-preventive-healthcare-185363.html
<![CDATA[News - PreveCeutical Medical applies to list on TSX-V ]]> https://www.proactiveinvestors.com.au/companies/news/184517/preveceutical-medical-applies-to-list-on-tsx-v-184517.html Health sciences group PreveCeutical Medical Inc (CSE:PREV, OTCQB:PRVCF) told investors it has filed  an application to list its shares on the TSX Venture Exchange as a Tier 2 issuer.

The group is developing innovative preventive therapies utilizing organic and nature identical products.

Last week it received a big boost - as it struck a research and development supply deal with a licensed producer (LP) of medical cannabis.

Under the deal, effective from September 18, the producer, licensed under the Canadian regulations, will supply PreveCeutical with cannabis oil and dried cannabis plant extract along with certain ingredients.

The firm will use these in its bid to commercialise sol-gels for the nasal delivery of medical compounds, including cannabinoids.

The group currently has five research and development programs.

These are dual gene therapy for curative and prevention therapies for diabetes and obesity; a Sol-gel platform for nose to brain delivery of medical compounds; Nature Identical peptides for treatment of various ailments; non-addictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions.

The group also sells CELLB9, an immune system booster

]]>
Mon, 25 Sep 2017 08:20:00 +1000 https://www.proactiveinvestors.com.au/companies/news/184517/preveceutical-medical-applies-to-list-on-tsx-v-184517.html
<![CDATA[News - PreveCeutical Medical hails deal with cannabis producer, which will boost its Sol-Gel programme ]]> https://www.proactiveinvestors.com.au/companies/news/184381/preveceutical-medical-hails-deal-with-cannabis-producer-which-will-boost-its-sol-gel-programme-184381.html Health sciences group PreveCeutical Medical Inc (CSE:PREV, OTCQB:PRVCF) says its Sol-Gel programme has received a big boost - as it struck a research and development supply deal with a licensed producer (LP) of medical cannabis.

Under the deal, effective from September 18, the producer, licensed under the Canadian regulations, will supply PreveCeutical with cannabis oil and dried cannabis plant extract along with certain ingredients.

The firm will use these in its bid to commercialise sol-gels for the nasal delivery of medical compounds, including cannabinoids.

Extremely pleased ...

"We are extremely pleased with the agreement between PreveCeutical and the LP," said Stephen Van Deventer, chairman and chief executive of PreveCeutical.

"The LP is an acknowledged industry leader in Canada in terms of its high-quality, high-margin derivative products that are manufactured under rigorous standards regarding processes, testing and transparency."

The group's Sol-Gel programme is trying to develop what is believed to be the first FDA approved, nose-to-brain delivery system of cannabinoids for the relief for a range of ailments, such as pain, inflammation, seizures, and neurological disorders.

READ: PreveCeutical Medical Inc upgrades to OTCQB to expand US shareholder base

Among the terms of the agreement, the firm will grant to the cannabis producer, non-transferable options to acquire shares in the firm worth a total of C$2mln at an exercise price equal to the closing price of the stock on the date of the deal.

The options will be exercisable for a period of 24 months from the effective date.

The LP will also have a right of first refusal to subscribe for the whole or a portion of any equity financing conducted by PreveCeutical for 24 months from the effective date of the agreement.

Shared advanced 5.48% to C$0.77 in Toronto..

]]>
Thu, 21 Sep 2017 08:16:00 +1000 https://www.proactiveinvestors.com.au/companies/news/184381/preveceutical-medical-hails-deal-with-cannabis-producer-which-will-boost-its-sol-gel-programme-184381.html
<![CDATA[News - PreveCeutical Medical Inc upgrades to OTCQB to expand US shareholder base ]]> https://www.proactiveinvestors.com.au/companies/news/184326/preveceutical-medical-inc-upgrades-to-otcqb-to-expand-us-shareholder-base-184326.html Health sciences group PreveCeutical Medical Inc (CSE: PREV, OTCQB: PRVCF) said shares began trading on the OTCQB Venture  Marketplace in the US on September 15.

The index is for early-stage and developing United States and international companies.

“We are extremely pleased to be able to upgrade to quote on the OTCQB.

"This listing will enable us to expand our US shareholder base as well as offer the company’s existing US shareholders a more transparent and efficient platform to obtain quotes and trade PreveCeutical securities," said PreveCeutical’s chairman and chief executive Stephen Van Deventer.

The group is developing innovative preventive therapies using organic and nature identical products and currently has five research and development programs.

These are dual gene therapy for curative and prevention therapies for diabetes and obesity; a Sol-gel platform for nose to brain delivery of medical compounds; Nature Identical peptides for treatment of various ailments; non-addictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions.

The group also sells CELLB9, an immune system booster.

]]>
Wed, 20 Sep 2017 15:54:00 +1000 https://www.proactiveinvestors.com.au/companies/news/184326/preveceutical-medical-inc-upgrades-to-otcqb-to-expand-us-shareholder-base-184326.html